Optiver Holding
GLUE icon

Optiver Holding’s Monte Rosa Therapeutics GLUE Stock Holding History

Optiver Holding’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.75K Sell
228
-38
-14% -$727 ﹤0.01% 1551
2025
Q4 		$4.17K Sell
266
-318
-54% -$4.29K ﹤0.01% 1499
2025
Q3 		$4.33K Buy
+584
New +$3.09K ﹤0.01% 1863

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Optiver Holding's GLUE Position: Q1 2026 in Review

Optiver Holding reduced its Monte Rosa Therapeutics (GLUE) stake by 14% in Q1 2026, selling an estimated $727 and leaving 228 shares worth $3.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1551.

Optiver Holding first reported a position in GLUE in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.33K in Q3 2025. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • Optiver Holding held 228 shares of Monte Rosa Therapeutics worth $3.75K as of Q1 2026.
  • Optiver Holding sold 38 Monte Rosa Therapeutics shares in Q1 2026, an estimated $727.
  • Monte Rosa Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #1551 holding.
  • Optiver Holding first reported a position in Monte Rosa Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Monte Rosa Therapeutics position peaked at $4.33K in Q3 2025.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.